SOX2 Is the Most Sensitive Biomarker in Testicular and Gynecologic Embryonic-type Neuroectodermal Tumors (ENT) Based on a Comprehensive Evaluation of Biomarker Expression
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Embryonic-type neuroectodermal tumors (ENTs) are distinct from Ewing sarcoma. SOX2 is the most sensitive biomarker for ENT diagnosis, with a panel including SOX2, OCT3/4, AE1/AE3, NKX2.2, CD99, and SOX17 aiding diagnosis.
Area Of Science
- Oncology
- Pathology
- Biomarker Research
Background
- Embryonic-type neuroectodermal tumors (ENTs) of the testis and gynecologic tract present diagnostic challenges.
- These tumors share features with small round blue cell tumors like Ewing sarcoma (ES) but are biologically distinct.
Purpose Of The Study
- To characterize 50 ENTs using 27 biomarkers to identify reliable diagnostic markers.
- To evaluate the utility of various biomarkers in differentiating ENTs from other small round blue cell tumors.
Main Methods
- Immunohistochemical analysis of 50 ENTs (38 testis, 12 gynecologic) using 27 biomarkers.
- Expression levels were quantified by combined staining scores (CS) ranging from 0-9.
Main Results
- SOX2 demonstrated the highest sensitivity, with 85% of ENTs showing a CS=9.
- GLUT-1, Fli-1, SALL4, and Cyclin D1 were positive in over half of the tumors.
- Traditional markers like synaptophysin, GFAP, S100, chromogranin-A, NKX2.2, CD99, and SOX17 showed limited utility, with CS ≥4 in fewer than half of the ENTs.
Conclusions
- SOX2 is a highly sensitive biomarker for ENT diagnosis.
- A diagnostic panel including SOX2, OCT3/4, AE1/AE3, NKX2.2, CD99, and SOX17 is recommended for ENT diagnosis in the appropriate clinical context.
- Many traditional biomarkers have limited utility for ENT diagnosis.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
